Growth Metrics

Protalix BioTherapeutics (PLX) Debt to Equity (2011 - 2024)

Protalix BioTherapeutics' quarterly Debt to Equity came in at $0.71 in Q2 2024, up 4.22% quarter-over-quarter from $0.69 in Q1 2024.

Protalix BioTherapeutics has reported Debt to Equity for 11 years, with the latest figure at $0.71 in Q2 2024.

  • For the quarter ending Q2 2024, Debt to Equity changed N/A year-over-year to $0.71; the trailing twelve-month figure through Jun 2024 stood at $0.71 (changed N/A YoY), and the FY2023 full-year result was $0.6, changed N/A from the prior year.
  • Debt to Equity for Q2 2024 stood at $0.71, up from $0.69 in the prior quarter.
  • The five-year high for Debt to Equity was $15.21 in Q3 2021, with the low at -$2.01 in Q4 2020.
  • Average Debt to Equity over 4 years is $4.28, with a median of $0.7 recorded in 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.06
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Protalix BioTherapeutics 164.49 Mn 153.70 Mn 29.62 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2024 0.71
Mar 31, 2024 0.69
Dec 31, 2023 0.60
Sep 30, 2023 0.53
Sep 30, 2021 15.21
Jun 30, 2021 14.67
Mar 31, 2021 3.82
Dec 31, 2020 -2.01
Mar 31, 2018 -0.17
Dec 31, 2017 -0.20
Sep 30, 2017 -0.39
Jun 30, 2017 -0.21
Mar 31, 2017 -0.06
Dec 31, 2016 -5.84
Sep 30, 2016 -0.28
Jun 30, 2016 -0.54
Mar 31, 2016 1.62
Dec 31, 2015 0.40
Dec 31, 2013 -0.09
Jun 30, 2013 -0.03
Mar 31, 2013 -0.43
Dec 31, 2012 -1.62
Sep 30, 2012 0.59
Jun 30, 2012 0.60
Dec 31, 2011 -0.25
Sep 30, 2011 -0.27
Jun 30, 2011 -0.51